The Social Security (Industrial Injuries) (Prescribed Diseases) Amendment Regulations 2017
The Secretary of State is satisfied of the matters referred to in section 108(2) of that Act.
Citation, commencement and interpretation1.
(1)
These Regulations may be cited as the Social Security (Industrial Injuries) (Prescribed Diseases) Amendment Regulations 2017 and come into force on 30th March 2017.
(2)
Amendment of regulation 4 of the Principal Regulations2.
Amendment of Schedule 1 to the Principal Regulations3.
(1)
(2)
In column 1—
(a)
“A1 Leukaemia (other than chronic lymphocytic leukaemia) or primary cancer of the bone, bladder, breast, colon, liver, lung, ovary, stomach, testis or thyroid.”;
(b)
in B6 omit the words “(including farmer’s lung)”;
(c)
“C34 Extrinsic allergic alveolitis.”;
(d)
in D9 omit the words “with obliteration of the costophrenic angle”.
(3)
In column 2—
(a)
“Exposure to ionising radiation where the dose is sufficient to double the risk of the occurrence of the condition.”;
(b)
in B6, after the words “heterologous proteins” insert “or any other biological substance that causes extrinsic allergic alveolitis” and at the end insert “; or (f) any other workplace”;
(c)
“Exposure to airborne isocyanates; or to any other chemical substance that causes extrinsic allergic alveolitis.”.
Signed by authority of the Secretary of State for Work and Pensions
These Regulations make amendments to the Social Security (Industrial Injuries) (Prescribed Diseases) Regulations 1985 (S.I. 1985/967) (“the Principal Regulations”).
Regulation 2 amends regulation 4(2) of the Principal Regulations to include new prescribed disease C34 (extrinsic allergic alveolitis).
Regulation 3 makes amendments to Schedule 1 to the Principal Regulations. It amends the prescriptions for prescribed diseases A1 (leukaemia (other than chronic lymphocytic leukaemia) or primary cancer of the bone, bladder, breast, colon, liver, lung, ovary, stomach, testis or thyroid), B6 (extrinsic allergic alveolitis) and D9 (unilateral or bilateral diffuse pleural thickening). It also inserts new prescribed disease C34.
A full impact assessment has not been published for this instrument as it has no impact on the private sector or civil society organisations.